Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
GST Demand Drop
Appellate Additional Commissioner (Chhattisgarh) largely dropped GST demand and penalties on wholly‑owned subsidiary Zydus Healthcare Ltd: FY2018‑19 reduced from Rs 28.7L to Rs 0.24L; FY2019‑20 reduced from Rs 13.2L to Rs 0.20L.
GST demand drop
Zydus Lifesciences' wholly owned subsidiary Zydus Healthcare received favourable appellate orders dropping GST demand and penalty for FY2018‑19 from Rs.28.7L to Rs.0.24L and for FY2019‑20 from Rs.13.2L to Rs.0.20L.
Share Buyback
Zydus Lifesciences launched a tender‑offer buyback of up to 87,30,158 equity shares at INR 1,260/share (aggregate up to INR 1,100 crore); Letter of Offer dispatched June 2; offer opens June 4 and closes June 10, 2026.
Buyback Announcement
Zydus Lifesciences announces a tender-offer buyback of up to 87,30,158 equity shares at INR 1,260/share (max INR 1,100 crore); Letter of Offer dispatched June 2 (Record Date May 29); offer opens June 4 and closes June 10, 2026.
Regulatory Warning
Zydus Lifesciences received a US FDA Warning Letter concerning purified talc at its Baddi formulation facility (from a records request, not an on‑site inspection); company says operations/supplies unaffected and will remediate.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at 1,106.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US. Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end. The product and innovation pipeline is advancing materially: Zydus plans to file an NDA for Saroglitazar Magnesium in the US imminently, has achieved several biosimilar and specialty milestones including a first‑in‑class Menkes disease approval (Zycubo), and holds licensing deals for large‑molecule biosimilars and a CE mark for its Andy robotic surgical system. Strategic M&A and partnerships are reshaping growth engines: full consolidation of Comfort Click doubled down Consumer Wellness scale (Q3 consumer revenue ▲113% YoY), acquisition of US biologics facilities from Agenus enables a Bio CDMO roadmap, and management retained a Rs. 5,000 crore QIP approval as an optional funding lever for future acquisitions. Geographic and portfolio diversification is visible: Pharma remains ~81% of sales with North America contributing 41% of revenues, India branded formulations outperformed the market with 14% growth, International Markets accelerated (▲38% YoY), and consumer wellness and MedTech are emerging, higher‑growth adjacencies supporting margin and top‑line resilience.
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.85 and a high of ₹1,115.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zydus Lifesciences Ltd has a market capitalization of approximately 1,09,422.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zydus Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.71 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,09,422.92 Cr, Zydus Lifesciences Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zydus Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 21.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock reacted to disclosures of USFDA observations at certain facilities, prompting an immediate risk reassessment by traders despite the company stating no data integrity issues.
The stock fell more than 2% intraday after Zydus disclosed it received a USFDA warning letter related to its formulations manufacturing facility at Baddi, Himachal Pradesh.
Zydus Lifesciences revised the buyback price to ₹1,260 per equity share from the earlier ₹1,150 per share.
Zydus said saroglitazar met the primary endpoint in the EPICS-III late-stage trial, with 48.5% of patients on 1 mg achieving a meaningful biochemical response versus placebo.
Bearish
4
Neutral
6
Bullish
4
Bearish
4
Neutral
6
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US.
Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end.
The product and innovation pipeline is advancing materially: Zydus plans to file an NDA for Saroglitazar Magnesium in the US imminently, has achieved several biosimilar and specialty milestones including a first‑in‑class Menkes disease approval (Zycubo), and holds licensing deals for large‑molecule biosimilars and a CE mark for its Andy robotic surgical system.
Strategic M&A and partnerships are reshaping growth engines: full consolidation of Comfort Click doubled down Consumer Wellness scale (Q3 consumer revenue ▲113% YoY), acquisition of US biologics facilities from Agenus enables a Bio CDMO roadmap, and management retained a Rs. 5,000 crore QIP approval as an optional funding lever for future acquisitions.
Geographic and portfolio diversification is visible: Pharma remains ~81% of sales with North America contributing 41% of revenues, India branded formulations outperformed the market with 14% growth, International Markets accelerated (▲38% YoY), and consumer wellness and MedTech are emerging, higher‑growth adjacencies supporting margin and top‑line resilience.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,09,423 Cr
Low Risk
21.7
33.7
21.2
4.0
1,115.00
835.85
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1390.00 | 1,12,149 Cr | 28.91 | 3.26 | 0.94 | 11.27 | 14.95 | 9.11 | ||
1086.85 | 1,09,423 Cr | 21.71 | 4.04 | 0.09 | 18.59 | 17.35 | 9.59 | ||
1275.00 | 1,06,483 Cr | 25.38 | 2.81 | 0.63 | 11.07 | 12.54 | 7.15 | ||
2252.60 | 1,02,996 Cr | 19.31 | 4.59 | 0.80 | 23.76 | 24.88 | 13.96 | ||
2350.00 | 97,383 Cr | 50.91 | 5.97 | 0.00 | 11.74 | 13.13 | 6.90 | ||
1446.00 | 84,324 Cr | 24.06 | 2.23 | 0.00 | 9.25 | 11.76 | 5.99 | ||
1404.55 | 75,881 Cr | 85.38 | 14.32 | 0.09 | 16.77 | 16.14 | 8.47 | ||
| Median: 7 Co. | — | 1404.55 | 1,02,996 Cr | 25.38 | 4.04 | 0.09 | 11.74 | 14.95 | 8.47 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
